ASDr. Ahmed ShihabConsultant Anesthesiologist – Baghdad عربي

Pharmacology of Opioids in Clinical Anaesthesia

Topic notes · Basic Sciences · Anaesthetic drugs

Opioid analgesics are the cornerstone of anaesthetic practice for providing surgical analgesia and controlling the response to pain. Safe use of this drug class requires a precise understanding of their cellular mechanisms, pharmacokinetic differences and acute adverse effects.

Cellular mechanism and respiratory effects

Opioids produce their analgesic effects mainly through G protein-coupled mu-opioid receptors. Activation of these receptors inhibits the enzyme adenylate cyclase and lowers cAMP levels, accompanied by inhibition of voltage-gated Ca2+ channels and increased K+ conductance, which reduces the excitability of neurones. Respiratorily, these drugs raise both the apnoeic threshold and the resting end-tidal PCO2, with marked depression of the ventilatory response to hypercapnia. Rapid intravenous injection of highly lipid-soluble compounds can also cause chest wall rigidity known as 'wooden chest', which is treated with neuromuscular blockers.

Pharmacokinetic differences and metabolism

Fentanyl is characterised by high lipid solubility that gives it rapid penetration of the blood-brain barrier and rapid redistribution, and it is metabolised in the liver by CYP3A4 to inactive norfentanyl. In contrast, Remifentanil is unique in having an ester bond that is rapidly hydrolysed by nonspecific esterases in blood and tissues to an inactive metabolite, which makes its context-sensitive half-time constant at about 3 minutes and completely independent of the duration of intravenous infusion.

Toxic risks in renal failure and reversal

Morphine is converted in the liver by the enzyme UGT2B7 into two main compounds: morphine-3-glucuronide (about 60%, lacking analgesia and causing neuroexcitation) and morphine-6-glucuronide (about 5–10%, active and more potent than the parent morphine). Both products are excreted by the kidneys, so M6G accumulates in renal failure, causing prolonged respiratory depression and coma. Similarly, Pethidine is converted to normeperidine, which has excitatory effects on the nervous system, accumulating renally and causing tremors, myoclonus and convulsions that are not reversible by Naloxone. Naloxone is a pure competitive antagonist at mu, kappa and delta receptors; its intravenous effect begins within 1–2 minutes and lasts only 30–60 minutes, a duration shorter than that of most agonists, which requires caution regarding re-narcotization. The chemoreceptor trigger zone in the area postrema also mediates the PONV caused by these drugs.

Key points
  • Opioids act through mu receptors to inhibit adenylate cyclase, lower cAMP and modulate Ca2+ and K+ channels.
  • Remifentanil has a constant context-sensitive half-time of 3 minutes thanks to its breakdown by nonspecific esterases.
  • M6G, produced by the metabolism of Morphine, accumulates in renal failure causing severe respiratory depression and prolonged sedation.
  • The Pethidine metabolite normeperidine causes neuronal convulsions in renal failure, the treatment of which does not respond to Naloxone.
  • The short duration of action of Naloxone (about 30–60 minutes) compared with opioids exposes the patient to the risk of recurrent depression (re-narcotization).

Sources

  • Basic Sciences in Anesthesia, p. 124
  • Basic Sciences in Anesthesia, p. 125
  • Basic Sciences in Anesthesia, pp. 128–129
  • Basic Sciences in Anesthesia, p. 130
  • Drugs in Anaesthesia and Intensive Care, 5th ed., pp. 278–279
  • Stoelting's Pharmacology & Physiology in Anesthetic Practice, 5th ed., p. 230

Test yourself: 7 questions on this topic and many more →

Educational content for healthcare staff and students. It does not replace clinical judgement or your hospital protocol; check any dose against the reference and local guidance before use.